Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxycodone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 8/20 | 0.96 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.96 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | BLM | P54132 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxycodone SCHEMBL8765516 | 0.98 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL13800804 | 0.98 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL1561081 | 0.98 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL13813558 | 0.98 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL1994014 | 0.98 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL10069639 | 0.98 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL2737 | 0.98 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL22058352 | 0.98 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL22163723 | 0.98 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL6745239 | 0.98 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6211 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075410-A | Dry powder composition for intranasal delivery | — | 2026-05-26 | — | — | CN | claimed |
| US-20250352480-A1 | TAMPER RESISTANT DOSAGE FORMS | PURDUE PHARMA LP (US) | 2025-11-20 | — | — | US | claimed |
| US-12396955-B2 | Tamper resistant dosage forms | PURDUE PHARMA L.P. (US) | 2025-08-26 | — | — | US | claimed |
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| US-20250235407-A1 | TAMPER RESISTANT DOSAGE FORMS | PURDUE PHARMA LP (US) | 2025-07-24 | — | — | US | claimed |
| US-12296043-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2025-05-13 | — | — | US | claimed |
| CN-119606905-A | Multi-unit sustained release tablet and preparation method thereof | 南通联亚药业股份有限公司 | 2025-03-14 | — | — | CN | claimed |
| US-12246094-B2 | Tamper resistant dosage forms | PURDUE PHARMA L.P. (US) | 2025-03-11 | — | — | US | claimed |
| CN-119574790-A | Method for measuring water content of abuse-proof preparation taking polyoxyethylene as matrix | 江苏恩华药业股份有限公司 | 2025-03-07 | — | — | CN | claimed |
| US-20250073173-A1 | TAMPER RESISTANT DOSAGE FORMS | PURDUE PHARMA LP (US) | 2025-03-06 | — | — | US | claimed |
| EP-0935523-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GENERAL MILLS, INC. (US) | 1999-08-18 | — | — | EP | claimed |
| WO-1999039698-A1 | SUSTAINED RELEASE FORMULATION | DURAMED PHARMACEUTICALS, INC. (US) | 1999-08-12 | — | — | WO | claimed |
| WO-1999032120-A1 | A METHOD OF PREVENTING ABUSE OF OPIOID DOSAGE FORMS | EURO-CELTIQUE, S.A. (LU) | 1999-07-01 | — | — | WO | claimed |
| EP-0900582-A1 | Method for removal of residual organic solvents from a crystalline bulk substance and use thereof in manufacturing pharmaceuticals | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1999-03-10 | — | — | EP | claimed |
| WO-1998018610-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | LENGERICH BERNHARD H VAN (US) | 1998-05-07 | — | — | WO | claimed |
| US-5656295-A | ORAL ADMINISTERING | EURO-CELTIQUE, S.A. (LU) | 1997-08-12 | — | — | US | claimed |
| US-5266331-A | Controlled release oxycodone compositions | EUROCELTIQUE, S.A. (LU) | 1993-11-30 | — | — | US | claimed |
| US-4486436-A | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same | ANALGESIC ASSOCIATES (US) | 1984-12-04 | — | — | US | claimed |
| US-4464376-A | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same | RICHARDSON-VICKS, INC. (US) | 1984-08-07 | — | — | US | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |